Epidemiological Prevalence of Phenotypical Resistances and Mobilised Colistin Resistance in Avian Commensal and Pathogenic E. coli from Denmark, France, The Netherlands, and the UK

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 4,1 MB, PDF-dokument

Colistin has been used for the treatment of non-invasive gastrointestinal infections caused by avian pathogenic E. coli (APEC). The discovery of mobilised colistin resistance (mcr) in E. coli has instigated a One Health approach to minimise colistin use and the spread of resistance. The aim of this study was to compare colistin susceptibility of APECs (collected from Denmark n = 25 and France n = 39) versus commensal E. coli (collected from the Netherlands n = 51 and the UK n = 60), alongside genetic (mcr-1–5) and phenotypic resistance against six other antimicrobial classes (aminoglycosides, cephalosporins, fluoroquinolones, penicillins, sulphonamides/trimethoprim, tetracyclines). Mini-mum inhibitory concentration (MIC) values were determined using a broth microdilution method (EUCAST guidelines), and phenotypic resistance was determined using disk diffusion. Colistin MIC values of APEC were significantly lower than those for commensals by 1 dilution (p < 0.0001, Anderson-Darling test), and differences in distributions were observed between countries. No isolate carried mcr-1–5. Three phenotypically resistant isolates were identified in 2/62 APEC and 1/111 commensal isolates. Gentamicin or gentamicin–ceftriaxone co-resistance was observed in two of these isolates. This study showed a low prevalence of phenotypic colistin resistance, with no apparent difference in colistin resistance between commensal E. coli strains and APEC strains.

OriginalsprogEngelsk
Artikelnummer631
TidsskriftAntibiotics
Vol/bind11
Udgave nummer5
ISSN2079-6382
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
This study was funded by Dopharma, VMD Livestock pharma, and Virbac through TransPharm. The PhD stipend of A.M. was covered by a Bloomsbury studentship. AM joined the London Interdisciplinary Biosciences Consortium cohort (Doctoral Training Partnership) as an RVC contribution and was supported by the Biotechnology and Biological Sciences Research Council (BBSRC). L.P., K.V., and P.D. are members of VetCAST and the European Network for Optimisation of Veterinary Antimicrobial Treatment (ENOVAT).

Funding Information:
Funding: This study was funded by Dopharma, VMD Livestock pharma, and Virbac through TransPharm. The PhD stipend of A.M. was covered by a Bloomsbury studentship. AM joined the London Interdisciplinary Biosciences Consortium cohort (Doctoral Training Partnership) as an RVC contribution and was supported by the Biotechnology and Biological Sciences Research Council (BBSRC). L.P., K.V., and P.D. are members of VetCAST and the European Network for Optimisation of Veterinary Antimicrobial Treatment (ENOVAT).

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

ID: 308121820